Please use this identifier to cite or link to this item: https://doi.org/10.1080/02841860600702076
DC FieldValue
dc.titleMulti-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma
dc.contributor.authorChuah, B.
dc.contributor.authorLim, R.
dc.contributor.authorBoyer, M.
dc.contributor.authorOng, A.-B.
dc.contributor.authorWong, S.-W.
dc.contributor.authorKong, H.-L.
dc.contributor.authorMillward, M.
dc.contributor.authorClarke, S.
dc.contributor.authorGoh, B.-C.
dc.date.accessioned2016-11-29T01:19:41Z
dc.date.available2016-11-29T01:19:41Z
dc.date.issued2007
dc.identifier.citationChuah, B., Lim, R., Boyer, M., Ong, A.-B., Wong, S.-W., Kong, H.-L., Millward, M., Clarke, S., Goh, B.-C. (2007). Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncologica 46 (2) : 234-238. ScholarBank@NUS Repository. https://doi.org/10.1080/02841860600702076
dc.identifier.issn0284186X
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/131526
dc.description.abstractHepatocellular carcinoma (HCC) is a hypervascular tumour, which overexpresses vascular endothelial growth factor. Thalidomide is an antiangiogenic agent with activity in refractory multiple myeloma. The purpose of this multi-centre phase II study was to evaluate the efficacy and toxicity of thalidomide in patients with advanced HCC. From February 2000 to November 2001, 37 patients with histologically proven, bi-dimensionally measurable advanced, unresectable HCC were enrolled. The starting dose of Thalidomide was 100 mg per day and escalated weekly by 100 mg to a maximum dose of 800 mg/day according to individual patient tolerance. Radiological tumour response and treatment related toxicities were prospectively assessed. Thirty-seven patients were evaluable for toxicity and 24 patients were evaluable for response. The median Thalidomide dose was 400 mg/day. There was no complete response (CR). One patient had a radiological partial response (PR) (3%; 95% confidence interval [95% CI], 0% to 8%) and six (16%) patients had stable disease for more than 6 months. Somnolence and fatigue were the most common side effects, occurring in 84% and 73% of patients respectively. Thalidomide monotherapy is tolerable and associated with modest antitumour activity in advanced HCC. © 2007 Taylor & Francis.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1080/02841860600702076
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1080/02841860600702076
dc.description.sourcetitleActa Oncologica
dc.description.volume46
dc.description.issue2
dc.description.page234-238
dc.description.codenACTOE
dc.identifier.isiut000244522200015
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

17
checked on Apr 4, 2020

WEB OF SCIENCETM
Citations

19
checked on Mar 18, 2020

Page view(s)

33
checked on Mar 27, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.